Merck & Co. Inc. (NYSE:MRK) announced results Tuesday from its Phase 3 HYPERION trial evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression.
In the study, Winrevair reduced the risk of clinical worsening events by 76%, as measured by a composite endpoint that included all-cause death, the need for non-planned PAH-related hospitalization, atrial septostomy, lung transplantation, or PAH deterioration.
